Author

M. Majem

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Practical recommendations for exercise and nutrition in patients with lung cancer.

Lung cancer (LC) is the leading cause of cancer mortality worldwide. Beyond pharmacological advances, lifestyle interventions such as exercise and nutrition have emerged as valuable adjuvant strategies. Preclinical and translational studies suggest that exercise may modulate molecular and immune pathways relevant to tu...

A. Cardeña-Gutiérrez, Teresa García Manrique, Laura Gutiérrez Sainz et al. · Clinical and Translational O... · 0 citations

Open access Sep 2026

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].

INTRODUCTION In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion. METHODS Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment c...

Yi-Long Wu, M. Majem, T. John et al. · Journal of Thoracic Oncology · 1 citation

Aug 2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

BACKGROUND Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...

H. Wakelee, J. Spicer, S. Gao et al. · Annals of Oncology · 1 citation